KRAS and plasma cell myeloma: For instance, the use of mut-KRAS patient-derived organoids and xenografts would represent an invaluable preclinical model to test novel proteasome inhibitors already in clinical trials for multiple myeloma, such as ONX 0914, carfilzomib, ixazomib and oprozomib.